Overview A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease Status: NOT_YET_RECRUITING Trial end date: 2027-03-01 Target enrollment: Participant gender: Summary To evaluate the safety and efficacy of BRM421 Ophthalmic Solution compared to vehicle for treatment of the signs and symptoms of dry eye disease (DED)Phase: PHASE2 Details Lead Sponsor: BRIM Biotechnology Inc.